NCT04329104View on ClinicalTrials.gov

Safety and Efficacy of CIS43LS Anti-malaria mAb in Mali

PHASE2CompletedINTERVENTIONAL
Enrollment

348

Participants

Timeline

Start Date

February 15, 2021

Primary Completion Date

January 26, 2022

Study Completion Date

July 5, 2023

Conditions
Plasmodium Falciparum InfectionMalaria
Interventions
BIOLOGICAL

VRC-MALMAB0100-00-AB (CIS43LS)

Administered via one-time intravenous infusion

OTHER

Normal saline

Administered via one-time intravenous infusion

Trial Locations (2)

Unknown

Kalifabougou MRTC Clinic, Kalifabougou

Torodo MRTC Clinic, Torodo

All Listed Sponsors
collaborator

Malaria Research and Training Center, Bamako, Mali

OTHER

collaborator

University of Washington

OTHER

collaborator

Harvard School of Public Health (HSPH)

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT04329104 - Safety and Efficacy of CIS43LS Anti-malaria mAb in Mali | Biotech Hunter | Biotech Hunter